An Australian entrepreneur has revealed the complete process of using AI to design mRNA cancer vaccines for pets, involving 300GB of genetic data and multi-model collaboration.

Paul Conyngham, founder of an Australian AI consulting firm, published an article on the X platform disclosing the complete technical process he used to design a personalized mRNA cancer vaccine for a pet dog using multiple AI chatbots. The dog was diagnosed with malignant mast cell carcinoma in May 2024. Subsequently, approximately 300GB of data was obtained through whole-genome and RNA sequencing. With the collaborative efforts of ChatGPT, Gemini, and Grok, target screening, protein structure modeling, and vaccine sequence design were completed, ultimately identifying the c-KIT gene mutation and screening for seven neoantigen targets. The vaccine was prepared by a research team at the University of New South Wales and administered at the University of Queensland's School of Veterinary Medicine. The overall treatment plan included the combined use of an mRNA vaccine, a tyrosine kinase inhibitor, and a PD-1 inhibitor, with the dosing sequence planned with AI assistance. After treatment began in December 2025, some tumors shrank within three months, but some unresponsive lesions still required surgical treatment. Experts point out that this case represents a single individual practice and does not constitute a universally applicable medical conclusion.